Breast cancer disease free survival. Medical search. Frequent questions

Anti-cancer drugs used in combination with surgery and/or radiation to destroy residual cancer cells to prevent or delay recurrence. (ucsfhealth.org)
Distant recurrence-free survival (DRFS). (orlandohealth.com)
This difference corresponded to a 26 percent overall reduction in the risk of cancer recurrence. (scienceblog.com)
However, the reduced risk of cancer recurrence and the low occurrence of side effects are encouraging, and further follow-up as well as other studies testing this approach will hopefully confirm the findings. (scienceblog.com)
This study demonstrates that daily use of a nonsteroidal anti-inflammatory drug (NSAID), which inhibits COX-2 activity, is associated with reduced estrogen receptor α (ERα)-positive breast cancer recurrence in obese and overweight women. (aacrjournals.org)
Breast carcinoma: pattern of recurrence and metastasis after mastectomy. (aaem.pl)
Insa A, LLuch A, Prosper F, Marguan I, Marginez-Agullo A, Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. (aaem.pl)
Their recurrence rate, she said, is comparable to reported rates of disease recurrence after standard mastectomy. (news-medical.net)
However, she said her team and most U.S. surgeons thoroughly remove the breast tissue under the "envelope" of breast skin and nipple because they believe that recurrence rates will be lower using this technique. (news-medical.net)
Conceivably, however, breast tissue could remain at the nipple-areola complex or skin flaps, which might lead to a cancer recurrence, the study authors wrote. (news-medical.net)
Therefore, in this study, they reviewed medical records of 297 patients whose breast cancer was treated with NSM from June 2007 through December 2012, to analyze rates and patterns of recurrence. (news-medical.net)
HER2-positive cancers, which make up about 20 percent of all breast cancers, are more aggressive and women with this form of breast cancer have a higher risk of disease recurrence and death. (cancer.gov)
Patients in the observation group who were disease free and did not have heart problems (a possible side effect of trastuzumab) were given the option of crossing over to receive trastuzumab because initial results of the HERA trial had shown a clear benefit in terms of reducing recurrence risk with 1 year of trastuzumab. (cancer.gov)
All participants were part of the Stress and Immunity Breast Cancer Project that examined the effectiveness of a psychological intervention program designed at Ohio State to help breast cancer patients better cope with the challenges of the disease and test if the intervention reduced the risk for recurrence. (medindia.net)
Previously published research by Andersen and her colleagues showed that the intervention did indeed reduce the risk for cancer recurrence. (medindia.net)
This study represents one of the biggest advances in the treatment of early breast cancer in recent decades and patients eligible to receive Verzenio ® (abemaciclib) (a population previously with a very poor prognosis) now have a therapeutic option that significantly improves their prognosis and their risk of recurrence', he explained. (euroweeklynews.com)
The prognosis of patients is mostly favourable in its initial stages, although certain profiles are up to three times more likely to experience recurrence, in many cases of incurable metastatic disease. (euroweeklynews.com)
Treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer−related morbidity and mortality. (medscape.com)
TNBCs are associated with high recurrence rates, rapid metastases, poor survival, and in- creased mortality compared with other histologic breast cancer subtypes. (bvsalud.org)

Eligible patients had received at least two prior therapies or T-DM1 for metastatic disease. (medpagetoday.com)
The study population had a median age of about 57, a median duration of metastatic disease of 3 to 3.5 years, and a median of four to five prior metastatic regimens. (medpagetoday.com)
Exemestane is an aromatase inhibitor that blocks the conversion of androgens to estrogen and may be superior to tamoxifen in patients with metastatic disease. (aafp.org)
Of the 388 patients that met inclusion criteria for this study, median overall survival (medOS) was 18.9 months in the total population, with no difference between patients with de novo metastatic disease (dnMBC -18.9 m) and recurrent metastatic disease (rMBC -18.7 m). (hindawi.com)
Eligible patients had centrally confirmed, measurable HER2-positive metastatic breast cancer without prior chemotherapy or trastuzumab for metastatic disease. (prnewswire.com)
Then, pertuzumab in 2012 and ado-trastuzumab emtansine in 2013 were approved in the US and elsewhere based on evidence showing an improvement in survival outcomes in patients with mostly trastuzumab naïve or trastuzumab-exposed metastatic disease. (carcinogenesis.com)
1 Approximately 5% to 10% of women diagnosed with breast cancer have metastatic disease at diagnosis, and up to 30% of women with early-stage breast cancer will develop metastatic disease. (biospace.com)
The U.S. Food and Drug Administration today approved a new drug to treat patients with advanced breast cancer, signaling a new strategy for arresting tumor growth and extending the time before cancer worsens in women with metastatic disease. (uclahealth.org)
The drug, Ibrance (palbociclib), was studied in 165 post-menopausal women with advanced estrogen-receptor positive (ER+) and HER2-negative (HER2-) breast cancer who had received no prior systemic therapy for their metastatic disease. (uclahealth.org)
A phase 2 study evaluated the drug in 165 post-menopausal women with advanced ER+/HER2- breast cancer who had not received prior systemic therapy for their metastatic disease. (uclahealth.org)
A few years later, doctors discovered that the breast cancer had returned as metastatic disease in her bones. (uclahealth.org)
as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)

In cancer, the development of blood vessels can feed tumors and allow them to grow, and drugs that block angiogenesis are being tested as cancer treatment. (ucsfhealth.org)
SAN ANTONIO - Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? (medscape.com)
However, a recent pooled analysis of more than 3500 patients across four trials, published in The Lancet Oncology in 2021, revealed that patients with HER2 low tumors had fewer grade 3 tumors, lower tumor proliferation, and improved disease-free survival (DFS), in particular, patients with hormone receptor negative (HR) disease. (medscape.com)
CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma , and brain tumors. (news-medical.net)
The CDX-011 antibody drug conjugate provides a targeted intervention for GPNMB expressing breast cancer, including patients with triple-negative disease' said Tom Davis, MD, Chief Medical Officer of Celldex Therapeutics, Inc. 'This Phase 2b trial will target patients whose tumors express GPNMB and is anticipated to include a significant proportion of patients with difficult-to-treat triple-negative tumors. (news-medical.net)
The study is a randomized, multi-center, controlled trial that will enroll 120 patients with heavily pre-treated, advanced breast cancer who are unlikely to benefit from any approved therapies and whose tumors are confirmed to express GPNMB via a validated, centralized diagnostic assay. (news-medical.net)
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. (duke.edu)
Approximately 70% of all breast cancers are considered HR positive, HER2 negative, meaning tumors test positive for estrogen and/or progesterone hormone receptors and negative for HER2. (biospace.com)
Experimental Design: We investigated ERβ by immunohistochemistry in 353 stage II primary breast tumors from patients treated with two years adjuvant tamoxifen, and generated gene expression profiles for a representative subset of 88 tumors. (lu.se)
To understand the relationship between Cxcl10 and ING4, researchers examined the METABRIC dataset containing the genomic data of breast tumors from more than 1,900 patients, representing all of the molecular subtypes of breast cancer. (tgen.org)
Unlike the non-TNBC type of breast cancers, TNBC tumors belong to the biologically aggressive type of breast cancer and cannot be managed with targeted, endocrine, or HER2/neu-directed therapies [ 4 - 6 ]. (hindawi.com)
Breast cancers are most often epithelial tumors involving the ducts or lobules. (msdmanuals.com)
General references Breast cancers are most often epithelial tumors involving the ducts or lobules. (msdmanuals.com)

Tumor size, lymph node status, Ki-67 score, metastasis, overall survival (OS), and disease-free survival (DFS) were retrieved from medical records. (nih.gov)
Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. (mdpi.com)
This study examines the influence of the heterogeneity of tumor proliferation on disease-free survival of patients with a breast carcinoma. (biomedcentral.com)
This slows or stops the growth of the tumor by preventing the cancer cells from getting the hormones they need to grow. (komen.org)
Multifocal disease is allowed, as long as the largest biopsied breast tumor was HER2-positive. (orlandohealth.com)
Furthermore, POGLUT2 knockdown of breast cancer cells was established, followed by in vitro biological function assays and in vivo tumor growth study. (frontiersin.org)
POGLUT2 was mainly expressed in stromal cells as verified by StromalScore, ESTIMATEScore, ImmuneScore, and Tumor purity, and POGLUT2 was positively correlated with cancer-associated fibroblasts, macrophages, monocytes, and neutrophils in the tumor microenvironment. (frontiersin.org)
Increased levels of POGLUT2 could result in the dysregulated immune cell infiltration and tumor microenvironment and showed a significant regulatory effect on the progression of breast cancer through Notch-related signaling. (frontiersin.org)
A biopsy is surgical removal of all or part of a suspected tumor/metastasis for examination under a microscope to check for cancer cells. (youngsurvival.org)
Tumor expression of Cxcl10 was initially characterized as a good prognostic indicator of therapy response in several cancers, including ovarian, colon and esophageal cancer. (tgen.org)
Strikingly, ING4-low/Cxcl10-high tumor patients had significantly reduced disease-free survival, suggesting a potential direct functional relationship. (tgen.org)
Palbociclib, Pfizer's drug for estrogen receptor-positive, HER2-negative locally advanced breast cancer, nearly doubled the time patients lived without tumor progression when administered in combination with the anti-estrogen drug letrozole, compared to letrozole alone, according to the results of the Phase II study PALOMA-1. (genomeweb.com)
Oral squamous cell carcinoma (OSCC) is the most common type of head and neck malignant tumor and is ranked the eighth leading cause of cancer worldwide. (nature.com)
Participants who have documented HER2- tumor, as assessed locally on a primary disease specimen and defined according to ASCO/CAP guidelines (Wolff et al. (who.int)

In addition, for those patients without central nervous system metastases at initial diagnosis, cancer progressed to the brain about 13 months after diagnosis. (medicalxpress.com)
If you (or a loved one) are dealing with a breast cancer diagnosis, or breast cancer treatment or recovery, check this list of related medical terms to better understand what it's all about. (ucsfhealth.org)
Does exemestane therapy improve outcomes in patients who have breast cancer when begun two to three years after diagnosis? (aafp.org)
Black women have poorer 5-year survival rates from breast cancer at all ages of diagnosis compared to white women. (medscape.com)
Ignorance about male breast cancer leads to long delays in diagnosis, reducing men's survival rate. (prwatch.org)
Since the public is repeatedly told that breast cancer is a woman's disease, men have difficulty accepting the diagnosis when they are affected, even to the point of keeping their diagnoses secret. (prwatch.org)
A neighbor of mine whose whose husband died of breast cancer (and who enlightened me about the toll the disease takes in men) told me that after his diagnosis, her husband's own friends jokingly derided him for having a "woman's disease. (prwatch.org)
They determined that ductal carcinoma in situ, in which cancer cells have not left the milk ducts, was the diagnosis in 23 percent of cases, and the other 77 percent had invasive cancer. (news-medical.net)
Two years after diagnosis, breast cancer survivors have four times more positive than negative thoughts about changes they experienced because of their illness, a new study found. (medindia.net)
Participants completed a "thought list" in which they wrote down ways their life had changed as a result of their cancer diagnosis and treatment. (medindia.net)
For example, under the "close relationships" category, they could say that a positive change was that their relationship with their husband was closer as a result of going through cancer diagnosis and treatment. (medindia.net)
Furthermore, cellspecific SATA uptake may have a broader use for molecularly guided diagnosis and therapy in other cancers. (lu.se)
Early diagnosis affords a better chance of survival and better prognosis [3]. (who.int)
Several methods are available for early diagnosis which give good results in early cancer stages. (who.int)
Survival is lower in black women than in white women at all stages of diagnosis (1). (cdc.gov)
The International Agency for Research on Cancer (IARC) has published Patterns of care for women with breast cancer in Morocco: an assessment of breast cancer diagnosis, management, and survival in two leading oncology centres on the eve of the launch of the Global Breast Cancer Initiative by the World Health Organization (WHO). (who.int)
The study involved more than 2000 patients with breast cancer and documented the changing patterns of care over a decade, from 2008 to 2017, including temporal variations in breast cancer characteristics, the level of improvement in access to cancer diagnosis and treatment over time, the variations in practices related to breast cancer treatment, and the time trend of disease-free survival for these patients. (who.int)
Patients with a confirmed diagnosis of breast cancer who were registered at the two oncology centres be- tween 2008 and 2017 were included in the retrospective study. (who.int)
In addition, they tients with breast cancer attend- interval between diagnosis and Chapter 2. (who.int)

Obesity is associated with a worse breast cancer prognosis and elevated levels of inflammation, including greater cyclooxygenase-2 (COX-2) expression and activity in adipose-infiltrating macrophages. (aacrjournals.org)
TNBC cases are generally treated by surgery, chemotherapy and carry a poor prognosis when compared with luminal breast cancer. (ecancer.org)
Conclusion: Expression of ERβ is an independent marker for favorable prognosis after adjuvant tamoxifen treatment in ERα-negative breast cancer patients, and involves a gene expression program distinct from ERα. (lu.se)
Over 100 free commonly used clinical formulas and calculator tools to help diagnose, treat, prevent, and determine prognosis of patients at point of care. (guidelinecentral.com)
this may be in part because they have a higher rate of triple-negative breast cancer (negative for estrogen and progesterone receptors and human epidermal growth factor receptor [HER2] oncogene), which has a poorer prognosis than other types. (msdmanuals.com)

An antibody-drug conjugate (ADC) targeting HER2 significantly slowed progression of previously treated metastatic breast cancer versus chemotherapy, a multinational randomized trial showed. (medpagetoday.com)
Median progression-free survival (PFS) improved from 4.9 months with investigator's choice of chemotherapy to 7.0 months with trastuzumab duocarmazine (SYD985). (medpagetoday.com)
Treatment with SYD985 significantly improved progression-free survival in comparison with standard physician's choice treatment in patients with HER2-positive metastatic breast cancer with two prior regimens or T-DM1 (trastuzumab emtansine, Kadcyla) in the metastatic setting," she said in conclusion. (medpagetoday.com)
Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. (orlandohealth.com)
The product of this enzyme, the proinflammatory eicosanoid prostaglandin E2 (PGE2), stimulates adipose tissue aromatase expression and subsequent estrogen production, which could promote breast cancer progression. (aacrjournals.org)
Activity endpoints will include response rate, progression-free survival (PFS) and overall survival (OS). (news-medical.net)
Moreover, POGLUT2 on survival and disease progression in pan-cancer was performed using TCGA data. (frontiersin.org)
A decrease in weight and insulin dose was more or less expected, however, we were surprised to discover a reduction in LDL-cholesterol and atherosclerosis progression with metformin treatment," said chief investigator John Petrie, MD, PhD. "The results of REMOVAL support wider prescribing of metformin to help reduce heart disease risk factors over a lifetime of type 1 diabetes, mirroring its current use in adults with type 2 diabetes. (pharmacytimes.com)
In this setting, the unmet need is high, and new therapeutic approaches are necessary to delay disease progression and extend survival," said Cristian Massacesi, MD, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca. (biospace.com)
The dual primary endpoints of TROPION-Breast01 are progression-free survival (PFS) assessed by blinded independent central review and overall survival. (biospace.com)
Some clinical studies indicate the assessment of CTCs can assist doctors in monitoring and predicting cancer progression and in evaluating a patient's response to therapy. (youngsurvival.org)
PHOENIX, Ariz. - Dec. 22, 2021 - What if the presence of a protein that indicates a robust immune response in some cancers, also could indicate the progression of malignancy in other types of cancers? (tgen.org)
Paradoxically, high expression of Cxcl10 also correlated with aggressive disease and poor patient survival in several cancers, including breast cancer, pancreatic cancer and melanoma, suggesting that Cxc10 may promote cancer progression in some settings. (tgen.org)
Breast cancer development and progression involve both germline and somatic mutations. (hindawi.com)
The randomized, Phase II PALOMA-1 trial was designed to assess whether palbociclib plus letrozole compared to just letrozole significantly improved progression-free survival in ER-positive, HER2-negative patients with locally advanced or metastatic breast cancer. (genomeweb.com)
At AACR, Richard Finn, associate professor of medicine at the University of California, Los Angeles and one of the study investigators, reported that patients in the palbociclib/letrozole combination arm had a median progression-free survival of 20.2 months compared to 10.2 months for those receiving just letrozole. (genomeweb.com)
This is statistically significant and an important median progression-free survival result in the context of current therapies. (genomeweb.com)
What I mean by that is this is the longest median progression-free survival ever reported in a randomized trial in first-line, ER-positive breast cancer. (genomeweb.com)
A multiyear phase 2 study found a significantly higher progression-free survival rate for patients with advanced ER+/HER2- breast cancer who were given palbociclib in addition to letrozole, a standard anti-estrogen treatment, compared with women who received letrozole alone. (uclahealth.org)
It showed progression-free survival was 20.2 months for patients who received palbociclib plus letrozole, compared with 10.2 months for those who received the letrozole alone. (uclahealth.org)
The results also indicated a 51 percent reduction in the risk of disease progression when palbociclib was used with letrozole. (uclahealth.org)
What is really remarkable is that we doubled the median progression-free survival," Finn said. (uclahealth.org)
Histopathological-based models may be used to stratify patients into low- and high-risk classes 9 and further identify patients at risk of aggressive early-stage OSCC, thus contributing to disease predictability in terms of clinical progression and treatment outcomes. (nature.com)
Data from FALCON showed that fulvestrant extended median progression-free survival (PFS) by 2.8 months compared with the aromatase inhibitor anastrozole. (medscape.com)
Approval of palbociclib for initial endocrine-based therapy in postmenopausal women was based on the phase II trial (PALOMA-1) which measured median progression-free survival (PFS) duration. (medscape.com)
The approval of palbociclib for ER+/HER2- advanced breast cancer in combination with fulvestrant in women (regardless of menopausal status) with disease progression following endocrine therapy was based on the PALOMA-3 trial (n=521). (medscape.com)

This study was conducted retrospectively at the two largest publicly funded oncology centres in Morocco: Centre Mohammed VI pour le traitement des cancers in Casablanca and Institut National d'Oncologie Sidi Mohamed Ben Abdellah in Rabat. (who.int)

The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed. (medicalxpress.com)
Ten to 16 percent of women with advanced breast cancer develop central nervous system metastases, the researchers wrote in their study, published in Clinical Cancer Research , a journal of the American Association for Cancer Research. (medicalxpress.com)
They evaluated how patients with HER2-positive breast cancer develop brain metastases , and followed them to examine what happens thereafter. (medicalxpress.com)
Of the 1,023 women newly diagnosed with HER2-positive metastatic breast cancer , 377 had central nervous system metastases. (medicalxpress.com)
Patients with central nervous system metastases were younger, and more likely to have hormone receptor negative disease and higher disease burden compared with those whose cancer did not spread to the brain. (medicalxpress.com)
Brain metastases-free survival (BMFS). (orlandohealth.com)
Researchers tested both dose dense and conventional chemotherapy regimens in 1,973 women with node-positive primary breast cancer and no other metastases. (scienceblog.com)
Is there a rationale for aggressive breast cancer liver metastases resections in Polish female patients? (aaem.pl)
Resection of Single Metachronous Liver Metastases from Breast Cancer Stage I-II Yeld Excellent Overall and Disease-Free Survival. (aaem.pl)
Predictive Profile-Normogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results Ann Surg Oncol. (aaem.pl)
This subtype accounts for approximately 20%-30% of invasive breast cancers, and until the discovery of effective anti-HER2 therapies ( first of which is trastuzumab), was associated with reduced disease-free survival (DFS), increased risk of metastases, and shorter overall survival (OS). (carcinogenesis.com)
While metastases often have the same characteristics as the initial breast cancer, they don't always. (youngsurvival.org)
Studies show that finding metastases early does not create better outcomes or lengthen survival. (youngsurvival.org)

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, and there is no approved targeted therapy. (nih.gov)
There was a 2% difference in 5-year overall survival among patients with advanced triple-negative breast cancer. (medscape.com)
Androgen receptor (AR) is one of the predominant nuclear hormone receptors in invasive breast cancer and can be explored as a biomarker of response for targeted anti-androgen therapy, especially in the setting of triple negative breast cancer (TNBC). (ecancer.org)
Triple negative breast cancer (TNBC) is defined by the absence of expression for oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) which has limited targeted therapeutic options. (ecancer.org)
However, the possible oncogenic interactions between germline genetic risk variants and somatic mutations in triple-negative breast cancer (TNBC) and non-triple-negative breast cancer (non-TNBC) have not been characterized. (hindawi.com)
Breast cancer is a heterogeneous disease comprising of two types, triple-negative breast cancer (TNBC) and non-triple-negative breast cancer (non-TNBC) [ 2 , 3 ]. (hindawi.com)
This double-blind RCT compares pembrolizumab (an immune checkpoint inhibitor with an average per treatment cost of $10.5K) combined with one of several chemotherapy options to chemotherapy and placebo in previously untreated metastatic triple-negative breast cancer (TNBC), a setting with high unmet patient need. (stopbreastcancer.org)

Women with HER2-positive breast cancer have a reasonable chance of living a long time with their disease, and they should be given aggressive therapy where appropriate," added Brufsky, professor of medicine and associate director of clinical investigation at the University of Pittsburgh Cancer Institute. (medicalxpress.com)
Patients with clinical stage T1-4, N0-3 disease at presentation and residual invasive disease postoperatively as defined above are eligible. (orlandohealth.com)
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact? (medscape.com)
Two leading clinicians debated whether the differences between the three groups have clinical relevance or whether the degree of HER2 expression is merely a marker for other disease processes. (medscape.com)
A new clinical trial has shown that reducing the interval between successive doses of a commonly used chemotherapy regimen improves survival in women whose breast cancer has spread to the lymph nodes. (scienceblog.com)
Breast cancer has been identified as a heterogeneous disease with marked differences in morphology, molecular biology, clinical findings and outcome [ 1 , 2 ]. (ecancer.org)
The clinical benefit demonstrated by those drugs in advanced disease has triggered several adjuvant and neoadjuvant trials testing them in combination with chemotherapy, but also without conventional chemotherapy, using single or dual HER2-targeting drugs. (carcinogenesis.com)
TROPION-Breast01 is the first pivotal trial of datopotamab deruxtecan in breast cancer and the third pivotal study in our clinical development program, underscoring our efforts to accelerate development of this TROP2 directed ADC in breast and lung cancer. (biospace.com)
Targeting this novel mechanism - a cascading cellular pathway that links ING4 to Cxcl10 and the proteins Egfr and Cxcr3 - may have a potential therapeutic benefit in ING4-deficient breast cancer, and Dr. Kim adds, those patients with an ING4 deficiency should be selected to participate in future clinical trials. (tgen.org)
Emily Tsutsumi, a graduate-student researcher in Clinical Translational Sciences at the UArizona medical school, and the study's lead author, said: "This study highlights a unique relationship between ING4 and Cxcl10 in aggressive breast cancer. (tgen.org)
This study focuses on TNBC and non-TNBC because both clinical and epidemiological studies have shown that TNBC has a poor outcome and survival rate when compared to non-TNBC [ 7 - 12 ]. (hindawi.com)
For decades, germline mutations, contained within the heritable genome, and somatic mutations, acquired de novo by breast cancer cells, have been considered as separate research endeavours, and each has unique clinical applications and implications for patient care. (hindawi.com)
The clinical benefit rate, including those who had stable disease for 24 weeks or more, was 81 percent for the combination treatment versus 58 percent for letrozole alone. (genomeweb.com)
With the FDA approval, this study represents a potential practice-changing result," said Dr. Dennis Slamon , director of the Revlon/UCLA Women's Cancer Research Program and director of clinical and translational research at the Jonsson Cancer Center. (uclahealth.org)
This led to a clinical study collaboration with Pfizer led by Finn and Slamon built on work at the Jonsson Cancer Center's Translational Oncology Research Laboratory. (uclahealth.org)
A phase 3 international clinical trial of the drug conducted by Finn and Slamon with Pfizer in approximately 660 people with advanced ER+/HER2- breast cancer has been completely enrolled. (uclahealth.org)
Dr. Sara Hurvitz , a UCLA oncologist and member of the Jonsson Cancer Center, told Klein about the clinical trial at UCLA. (uclahealth.org)
A nomogram based on MRI radiomics and clinical variables can predict whether hormone receptor (HR)-positive breast cancer patients will respond to endocrine therapy, according to research published online September 11 in the Breast . (auntminnie.com)
A team of researchers from China developed a model that combined preoperative MRI radiomics with significant clinical and pathological information to predict endocrine resistance in HR-positive nonmetastatic breast cancer patients. (auntminnie.com)
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. (cdc.gov)
In 1986, breast cancer (International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 174) was the underlying cause of death for 40,534 women in the United States. (cdc.gov)
The two principal modes established for secondary prevention are clinical breast examination and mammography (13). (cdc.gov)
To assess the efficacy of combined mammography and physical breast examination in reducing breast cancer mortality, a large randomized clinical trial was conducted at the Health Insurance Plan in New York City in the mid-1960s (14). (cdc.gov)

Learn about aromatase inhibitors and other hormone therapies for metastatic breast cancer . (komen.org)
This study was aimed to identify high-risk endocrine-resistance patients with HR-positive breast cancer in advance, provide patients with personalized therapeutic agent such as CDK4/6 inhibitors or other targeted therapies, and prolong disease-free survival," the authors wrote. (auntminnie.com)

In addition, CM from macrophage/preadipocyte cocultures exposed to sera from obese patients stimulated greater breast cancer cell ERα activity, proliferation, and migration compared with sera from normal-weight patients, and these differences were eliminated or reduced by the addition of an aromatase inhibitor during CM generation. (aacrjournals.org)

The study involved a series of 368 patients from the François Baclesse Cancer Centre (Caen) treated for a breast carcinoma between 1991 and 1995, whitout neoadjuvant therapy and with a follow-up of more than 15 years. (biomedcentral.com)
Another study presented at SABCS 2022, which involved patients with early-stage invasive lobular carcinoma of the breast, suggested that HER2 low status was associated with worse DFS when compared to HER2-negative status, as well as progesterone receptor positivity. (medscape.com)
Breast cancer is the most commonly diagnosed cancer among US women, with an estimated 268,600 newly diagnosed women with invasive disease (48,100 cases of ductal carcinoma in situ [DCIS]) in 2019, accounting for approximately 15.2%-30% of all new cancer cases among women, depending on the data sources. (medscape.com)
These results may be highly clinically significant, as in the U.S. alone, approximately 10,000 women are diagnosed annually with ERα-negative/ERβ-positive breast carcinoma who may benefit from adjuvant tamoxifen. (lu.se)
Other studies in oral cancer [23,24] reported that there is no relationship between the histopathological grade of oral epithelial dysplasia or oral squamous cell carcinoma and the ploidy status. (researchgate.net)

Among postmenopausal women with hormone receptor-positive breast cancer, aromatase inhibitors (alone or after tamoxifen) offer the same or slightly greater benefit compared to tamoxifen alone [ 88,105-108 ]. (komen.org)
Tamoxifen is the current standard of care for the treatment of estrogen-receptor-positive breast cancer in postmenopausal women. (aafp.org)
Exemestane improves outcomes for postmenopausal women with estrogen-receptor-positive breast cancer when given for two to three years after a two- to three-year course of treatment with tamoxifen. (aafp.org)
I believe palbociclib will now become a standard treatment approach for postmenopausal women with ER+/HER2- metastatic breast cancer. (uclahealth.org)
Fulvestrant (Faslodex) was approved by the FDA for hormone receptor (HR)-positive, HER2-negative locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. (medscape.com)
Palbociclib and ribociclib are cyclin-dependent kinases (CDK) 4, 6 inhibitors indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. (medscape.com)
Approval of ribociclib was based on interim analysis results from the pivotal phase 3 MONALEESA-2 trial in postmenopausal women who received no prior systemic therapy for their advanced breast cancer. (medscape.com)

Approximately 20% to 30% of primary breast cancers are HER2-positive. (prnewswire.com)

The results, combined with those of the precedent-setting DESTINY trial of trastuzumab deruxtecan (T-DXd), suggest that optimal sequencing of treatment for metastatic HER2-positive breast cancer will change in the near future, said ESMO invited discussant Barbara Pistilli, MD, of Gustave Roussy Cancer Center in Villejuif, France. (medpagetoday.com)

Brufsky and colleagues used data from the registHER study to evaluate the incidence, potential risk factors and outcomes for patients with HER2-positive breast cancer. (medicalxpress.com)
These authors concluded that it is "unclear whether these slight differences in outcomes justify classification of HER2 low disease as a unique subtype," although the use of novel antibody-drug conjugates could "drastically change" outcomes, Curigliano commented. (medscape.com)
The Auckland Advanced Breast Cancer Review (AABC) was a review of patients diagnosed with advanced inoperable/metastatic breast cancer (ABC) within the Auckland region of New Zealand, commissioned in response to a Breast Cancer Registry report (BCFNZR) that showed poor and inequitable survival outcomes. (hindawi.com)
While treatment uptake and survival outcomes were generally comparable across ethnicity and district health boards, dnMBC survival outcomes were considerably poorer than expected, earmarking this subset of patients with ABC for more in-depth research. (hindawi.com)
Despite improvements in treatment options and survival outcomes in recent years, NZ ABC mortality rates continue to exceed the OECD average [ 1 ]. (hindawi.com)
Despite observable gains in survival outcomes over the 15-year period, the BCFNZR findings were disappointing. (hindawi.com)
Maori health outcomes have historically lagged behind non-Maori across a range of cancer and noncancer related indicators [ 7 ]. (hindawi.com)
This inequity was reflected in the BCFNZR, where Maori had the poorest survival outcomes amongst patients with ABC compared to all other ethnicities in NZ, with a medOS of only 12.8 months. (hindawi.com)
Secondary endpoints include PFS assessed by investigator, objective response rate, duration of response, disease control rate, and patient reported outcomes, as well as safety and pharmacokinetics. (biospace.com)
Cxcl10 also is expressed in cancer cells, where it is an indicator of both positive and negative outcomes. (tgen.org)
In addition, they found that high expression of the CXCL10 gene was associated with poor patient outcomes in breast cancer. (tgen.org)
This publication summarizes the outcomes of a patterns-of-care study implemented by IARC in collaboration with the Ministry of Health of the Kingdom of Morocco and the Lalla Salma Foundation for Cancer Prevention and Treatment, to assess how far state-of-the-art cancer diagnostics and therapy have been disseminated into routine oncology practice in Morocco. (who.int)

White, Asian, and Pacific Islander women are more likely to be diagnosed with localized breast cancer than Black, Hispanic, American Indian, and Alaska Native women. (msdmanuals.com)

HER2-positive breast cancer is an aggressive form of breast cancer that tests positive for the human epidermal growth factor receptor 2 (HER2), which promotes cancer cell growth. (prnewswire.com)
PURPOSE: To define the biology driving the aggressive nature of breast cancer arising in young women. (duke.edu)
A critical challenge faced by clinicians and patients is the identification of patients at high risk of developing aggressive disease that could guide the application of precision medicine and precision prevention in TNBC and non-TNBC. (hindawi.com)

While previous research has evaluated the use of various forms of "dose dense" chemotherapy, this is the first major controlled study to show a clear survival benefit for women with node-positive breast cancer. (scienceblog.com)
Axillary dissection may be considered in cases of node-positive breast cancer. (medscape.com)

Based on these study results, lead researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now know that these women should get trastuzumab and potentially chemotherapy, even if cancer spreads to the brain. (medicalxpress.com)
It is surprising that chemotherapy/trastuzumab adds to these women's survival," Brufsky said. (medicalxpress.com)
BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH , Aug. 25, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) announced today that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Application (MAA) for a proposed biosimilar Trastuzumab, which is used to treat certain HER2-positive breast and gastric cancers. (prnewswire.com)
The regulatory submission for proposed biosimilar Trastuzumab in Europe takes us a step closer towards enabling affordable access to this critical biologic therapy for the treatment of HER2-positive breast cancer. (prnewswire.com)
Mylan has exclusive commercialization rights for the proposed biosimilar Trastuzumab in the U.S., Canada , Japan , Australia , New Zealand , the European Union and European Free Trade Association countries. (prnewswire.com)
Trastuzumab is indicated for the treatment of certain HER2-positive early stage and metastatic breast cancer as well as HER2-positive metastatic gastric cancer. (prnewswire.com)
The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial. (carcinogenesis.com)
Treatment with trastuzumab (Herceptin®) for 1 year following standard chemotherapy improved disease-free survival in women with HER2-positive early breast cancer. (cancer.gov)
After a median follow-up of 4 years, 79 percent of women in the trastuzumab group were disease free, compared with 72 percent in the observation group. (cancer.gov)
Patients in the trastuzumab group had a roughly 24 percent lower risk of disease [than those in the observation group], and the difference between groups was highly statistically significant . (cancer.gov)
Trastuzumab extends survival of women with HER2-overexpressing metastatic breast cancer, and the HERA trial is one of several trials that were initiated to determine whether this treatment would benefit patients with early-stage disease as well. (cancer.gov)
The latest analysis "provides further assurance" that giving trastuzumab after standard chemotherapy is effective for treatment of early HER2-positive breast cancer and that such treatment "continues to show a generally favorable safety profile with a low rate of congestive heart failure," Dr. Joensuu wrote. (cancer.gov)
Trastuzumab after Chemotherapy Is Effective in HER2-Positive Breast Cancer was originally published by the National Cancer Institute. (cancer.gov)
The biggest news coming out of ESMO 2021, largely described as "practice-changing," were the early results of DESTINY-Breast03 , which is an ongoing head-to-head randomized controlled trial (RCT) comparing Enhertu (trastuzumab deruxtecan) with Kadcycla (trastuzumab emtansine [T-DM1])[1] in the second-line setting of HER2+ unresectable and/or metastatic breast cancer. (stopbreastcancer.org)
The bacteriostatic water for injection is a colourless, transparent solution, free of visible particles and is intended to use for the reconstitution of [BT-ON014 trade name] to yield a multi-dose solution containing 21 mg/mL trastuzumab at a pH of approximately 6.0. (who.int)

Of 61 TNBC cases analysed, 37.7% were AR positive and 62.3% were AR negative, making the latter to become quadruple negative breast cancers. (ecancer.org)
This warrants further exploration of the predictive and prognostic significance of its expression amongst TNBC and the potential for targeted therapy, specifically androgen antagonists to improve the outcome of this disease with limited therapeutic options. (ecancer.org)
TNBC accounts for 170,000 cases of the global breast cancer burden and has been associated with disparities in racial incidence [ 3 ]. (ecancer.org)
Here, we delineated the possible oncogenic interactions between genes containing germline and somatic mutations in TNBC and non-TNBC and investigated whether there are differences in gene expression and mutation burden between the two types of breast cancer. (hindawi.com)
Among the signalling pathways discovered included the DNA repair and Androgen and ATM signalling pathways for TNBC and the DNA damage response, molecular mechanisms of cancer, and ATM and GP6 signalling pathways for non-TNBC. (hindawi.com)
The results show that integrative genomics is a powerful approach for delineating oncogenic interactions between genes containing germline and genes containing somatic mutations in TNBC and non-TNBC and establishes putative functional bridges between genetic and somatic alterations and the pathways they control in the two types of breast cancer. (hindawi.com)
The majority of breast cancers are non-TNBC [ 2 , 3 ]. (hindawi.com)
The TNBC types are defined as breast cancers that lack expression of the oestrogen receptor (ER) and progesterone receptor (PR) and lack amplification of the human epidermal growth factor receptor 2 (HER-2) [ 4 - 6 ]. (hindawi.com)
2021), unlike the more common hormone-dependent cancers that develop with a lifetime of estrogen exposure, the relative rates of TNBC are higher in younger patients, being more common in patients aged 20 to 39 years. (bvsalud.org)

Moreover, increased gene mutation and amplification, methylation, and CNA of POGLUT2 were found in several types of cancers. (frontiersin.org)

I. To determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the control arm (T-DM1 + placebo) when administered to high risk patients with HER2-positive breast cancer and residual disease after neoadjuvant HER2-directed therapy. (orlandohealth.com)

Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. (duke.edu)

Zielinski J, Jaworski R, Irga-Jaworska N, Haponiuk I, Jaskiewicz J. The significance of ductoscopy of mammary ducts in the diagnostics of breast neoplasms. (aaem.pl)

This approach has already been used to treat early-stage breast cancers of the HR+HER2- or luminal subtype. (euroweeklynews.com)
Approximately 70 per cent of all breast cancer cases are the HR+, HER2- subtype. (euroweeklynews.com)

While CXCR4's expression is low or absent in many healthy tissues, it was demonstrated to be expressed in over 23 types of cancer, including breast cancer, ovarian cancer, melanoma, and prostate cancer. (wikidoc.org)
to document the practices relat- cancer (other than non-melanoma ed to comprehensive treatment skin cancer) were also excluded. (who.int)

For a few patients, the pathol- targeted therapy, and pal iative care), in the case records at the two ogy report confirming cancer diag- fol ow-up, and vital status data. (who.int)

Approximately 300 patients are diagnosed with advanced breast cancer (ABC) in New Zealand (NZ) annually. (hindawi.com)
[ 5 , 6 ] The rate of increase in breast cancer incidence continues throughout life but slows substantially after menopause, to approximately 2%-3% per year. (medscape.com)
With approximately 18,000 new cases of BC diagnosed in Polish women annually, breast cancer liver metastasis (BCLM) is respectively an increasing issue. (aaem.pl)
1 Approximately 70% of all breast cancers are considered HR positive, HER2 negative. (biospace.com)
Approximately 10% of patients treated with Enhertu developed ILD in the single-arm trial that led to the accelerated approval of this drug in the third-line setting of HER2+ metastatic breast cancer. (stopbreastcancer.org)

In the analysis of prognostic factors, disease free survival was used as the end point. (biomedcentral.com)

Cancer and its related mortality are one of the most serious public health problems worldwide ( 1 ). (frontiersin.org)
Banas T, Juszczyk G, Pitynski K, Nieweglowska D, Ludwin A, Czerw A. Incidence and mortality rates in breast, corpus uteri, and ovarian cancers in Poland (1980-2013): an analysis of population-based data in relation to socioeconomic changes. (aaem.pl)
Breast cancer is one of the world's leading causes of mortality in women 35 years of age or more [1]. (who.int)
Breast cancer incidence and mortality in the United States and worldwide have increased in cohorts of women born since 1900, for reasons not well understood (3,4). (cdc.gov)
Age-adjusted rates of breast cancer mortality were 12% higher in black women than in white women (5). (cdc.gov)
When age-adjusted to the 1986 U.S. population, breast cancer mortality rates in 1986 were generally lower in southern states and higher in northern states (Table 1, Figure 1). (cdc.gov)
Nonuse increases with age and is thus inversely associated with risk of breast cancer mortality. (cdc.gov)

Interestingly, the metastasis free interval (mFI: 30 months) amongst patients who developed metastatic relapse after early breast cancer was similar to international standards. (hindawi.com)
[12] [13] However, in breast cancer where SDF1/CXCL12 is also expressed by the cancer cells themselves along with CXCR4, CXCL12 expression is positively correlated with disease free (metastasis free) survival. (wikidoc.org)

With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. (carcinogenesis.com)

Activity of VEGF-A, as its name implies, has been studied mostly on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g., stimulation monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). (wikipedia.org)

Breast cancer(BC) is the most frequent neoplasm in women of the west countries. (isciii.es)
Aromatase inhibitors are used to treat breast cancer in women. (komen.org)
All of the women were postmenopausal, had normal renal and liver function, and had an estrogen-receptor-positive primary breast cancer. (aafp.org)
This study suggests that many women with breast cancer may benefit from chemotherapy administered on a condensed schedule," said Marc L. Citron, M.D., Albert Einstein College of Medicine, who is the lead investigator of the study. (scienceblog.com)
With the availability of new drugs to control one of the most serious side effects of chemotherapy administration, we can further increase the chances of survival for women with breast cancer. (scienceblog.com)
[ 2 ] ) Each year, nearly 42,000 women die of breast cancer, making it the second-leading cause of cancer deaths among US women after lung cancer. (medscape.com)
1982 Average annual breast cancer incidence per 100,000 women by age in San Francisco, United States, Japan, and China. (medscape.com)
A detailed analysis of SEER data from 1975-2004 included 440,653 cases of breast cancer and showed a consistent finding of higher age-specific incidence of breast cancer among black women compared to white women younger than 40 years. (medscape.com)
This poorer survival can be attributed, in part, to the tendency of black women to be diagnosed at later stages of the disease. (medscape.com)
According to a study from the American Cancer Society (ACS), in 2012, the breast cancer rates converged among black and white women even though white women have historically had higher incidence rates. (medscape.com)
After all, lung cancer kills twice as many women each year as breast cancer -- more women every year in the U.S. die from lung cancer than from breast, uterine, and ovarian cancers combined . (prwatch.org)
In 2009 alone, 31,000 more women died of lung cancer than breast cancer. (prwatch.org)
Men are at a diagnostic disadvantage for the disease because they are not urged to conduct self-exams or get screening mammograms the way women are. (prwatch.org)
Breast cancer (BC) makes up nearly 26% of malignant tumours worldwide and is the leading cause of cancer-related deaths in European women. (aaem.pl)
Worldwide, nearly 2 million women are diagnosed with breast cancer each year, making it the second most common cancer in the world. (prnewswire.com)
A recessive variant of XRCC4 predisposes to non- BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. (duke.edu)
Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed, findings of a single-center study show. (news-medical.net)
More women are requesting NSM because of the superior cosmetic results, but doctors don't want to take any chances with breast cancer patients' safety for the sake of cosmetic improvement," Dr. Smith said. (news-medical.net)
More than three-fourths of the women had stage 0 or stage 1 breast cancer, and the remainder had stage 2 or 3 cancer, the investigators reported. (news-medical.net)
Both looked at the length of time women remained free of cancer after treatment (disease-free survival). (oncologynurseadvisor.com)
The POEMS-SWOG S0230 trial looked at women with hormone-receptor-negative breast cancer. (oncologynurseadvisor.com)
The women had improved disease-free survival if they received LHRHa. (oncologynurseadvisor.com)
Furthermore, the PROMISE-GIM6 study found that adding LHRHa made no difference to disease-free survival, even within the subgroup of women with hormone-receptor-positive breast cancer, who accounted for the majority of the patients enrolled in the study. (oncologynurseadvisor.com)
With the rising trend of delaying childbearing, more breast cancer patients are diagnosed without having completed their families and thus it is vital to provide reliable fertility preservation methods for these young women. (oncologynurseadvisor.com)
The study involved 160 women who were diagnosed with Stage II or III breast cancer and were being treated at Ohio State's Arthur G. James Cancer Hospital or by other physicians in the Columbus area. (medindia.net)
Cancer survivors who went through the intervention program were especially positive: On average, they listed 13 positive changes that occurred to them, compared to 10 positive changes for women in the control group. (medindia.net)
Breast cancer is the second most diagnosed malignancy and the second leading cause of cancer-related deaths among women in the US [ 1 ]. (hindawi.com)
In 2018, there were 266,120 new cases of breast cancer diagnosed among women and 40,920 women died from the disease in US [ 1 ]. (hindawi.com)
We are not selecting patients [by biomarkers] because we didn't find that any of the biomarkers used in part two improved our ability to detect women who will benefit from palbociclib any better than women with ER-positive breast cancer," Rothenberg said. (genomeweb.com)
Over 80 percent of the women in the study with metastatic ER+ breast cancer received some benefit from the treatment. (uclahealth.org)
Sixty percent of all women diagnosed with this disease have my variety, and this drug having this sort of an impact, so fast and so effectively, is earth shattering. (uclahealth.org)
While providing additional options to men and women with metastatic breast cancer who face limited "good" treatment options, both drugs come with toxicities. (stopbreastcancer.org)
Asian and Pacific Islander women have the lowest death rate from breast cancer. (msdmanuals.com)
Although BSE is a simple, quick and cost-free procedure, it appears that many women either perform it erratically or not at all. (who.int)
Breast cancer accounted for 32% of diagnosed cancers and 20% of cancer deaths among women (1). (cdc.gov)
54% of deaths from breast cancer in the United States in 1986 occurred in women greater than or equal to 65 years of age (2). (cdc.gov)
and survival in women diagnosed with 'regional' or 'distant' breast cancer is substantially lower. (cdc.gov)
Editorial Note: Risk factors for breast cancer among women include exposure to radiation, a history of breast cancer in close female relatives, early menarche and late menopause, nulliparity, and childbearing at older ages (6). (cdc.gov)
Based on this study, at least 19% of breast cancer deaths among women in the United States can be estimated to be attributable to nonuse of mammography (Table 2). (cdc.gov)
Men also die from breast cancer (ICD-9-CM 175), but at less than 1/100th the rate among women (2). (cdc.gov)
Breast cancer is the most common cancer in women. (cdc.gov)
Studies also show higher rates of death related to breast cancer among women with a disability, even when diagnosed at the same stage as women without a disability. (cdc.gov)
Disparities in breast cancer treatment and survival for women with disabilities. (cdc.gov)

In this article, we review the current data on the therapeutic management of HER2-positive early-stage breast cancer in the adjuvant and neoadjuvant setting. (carcinogenesis.com)

Méthodologie: Entre septembre 2021 et février 2022, des écouvillonnages oropharyngés et/ou nasopharyngés de travailleurs symptomatiques COVID-19 et apparemment en bonne santé sélectionnés consécutivement du site minier de Wahgnion dans le sud-ouest du Burkina Faso qui ont consenti à l'étude ont été prélevés selon les deux programme de quart de semaines et testé pour le SRAS-CoV-2 à l'aide d'un test RT-PCR. (bvsalud.org)

Centers for Disease Control and Prevention. (cdc.gov)
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. (cdc.gov)

2000 treated cases of breast can- graphic characteristics of pa- at the oncology centre, and the cer in the study. (who.int)

For a summary of research studies on aromatase inhibitors and early breast cancer, visit the Breast Cancer Research Studies section . (komen.org)
In the Phase III OlympiA trial, Lynparza® (olaparib) reduced the risk of cancer recurrences or death by 42 percent in patients with BRCA-mutated high-risk early breast cancer. (europeanpharmaceuticalreview.com)
The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients. (europeanpharmaceuticalreview.com)
When used in conjunction with endocrine therapy to treat early breast cancer patients, 'abemaciclib' has reportedly shown great efficacy against early breast cancer of the HR+HER-type, one of the most common forms of this neoplasia. (euroweeklynews.com)

PALOMA-1 was split into two parts, wherein the first part included 66 patients with ER-positive, HER2-negative advanced breast cancer and the second part examining 99 patients with ER-positive, HER2-negative disease and specific biomarkers, including cyclin D1 amplification, p16 loss, or both. (genomeweb.com)

The researchers found that two dose dense regimens provided significantly higher disease-free survival rates than two regimens using conventional dosing, and that efficacy did not differ between the two dose dense regimens. (scienceblog.com)
Among patients on the dose dense regimens, disease-free survival was 82 percent after four years, compared to 75 percent for those who received conventional therapy. (scienceblog.com)
2 For patients with HR positive, HER2 negative metastatic breast cancer that progresses on or is not suitable for hormone therapy-based regimens, current standard of care is single-agent chemotherapy, which demonstrates diminishing efficacy with each subsequent line of treatment. (biospace.com)

The group first retrospectively gathered data from 744 newly diagnosed nonmetastatic HR-positive breast cancer patients from three hospitals in China. (auntminnie.com)

Generic name for Arimidex, a hormone therapy for advanced breast cancer. (ucsfhealth.org)
Brand name for anastrazole a hormone therapy for advanced breast cancer. (ucsfhealth.org)
They are used to treat hormone receptor-positive early , locally advanced and metastatic breast cancers. (komen.org)
Hormone receptor-positive breast cancers need estrogen and/or progesterone (female hormones) to grow. (komen.org)
These hormone-receptor-positive cancers have receptors on the cell surface that trigger the cancer's growth in response to circulating hormones. (oncologynurseadvisor.com)
HR+, HER2- breast cancers , also called luminal or hormone-sensitive, constitute around 70 per cent of all cases of this disease. (euroweeklynews.com)

All patients included had long-term diabetes and 3 or more cardiovascular disease risk factors, such as body mass index over 27, A1C greater than 8, known heart disease, smoking, high blood pressure, high cholesterol/triglycerides, family history of cardiovascular disease, or diabetes duration longer than 20 years, according to the session. (pharmacytimes.com)

SYD985 can provide a new treatment option for patients with pretreated locally advanced or metastatic breast cancer," she added. (medpagetoday.com)

Anatomy12

Organisms3

Diseases56

Chemicals and Drugs57

Analytical, Diagnostic and Therapeutic Techniques and Equipment79

Psychiatry and Psychology2

Phenomena and Processes43

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena2

Humanities1

Information Science7

Named Groups2

Health Care33

Geographicals2

Recurrence19

Metastatic disease13

Tumors13

Tumor14

Diagnosis19

Prognosis5

Progression26

Traitement des cancers1

Metastases13

Triple-Negati7

Clinical23

Therapies2

Proliferation1

Carcinoma5

Postmenopausal women7

Primary breast cancers1

Treatment for metastatic1

Outcomes12

Diagnosed with localized breast cancer1

Aggressive3

Node-positive2

Trastuzumab15

TNBC9

Types of cancers1

Invasive disease-free survival1

Heterogeneous disease1

Neoplasms1

Subtype2

Melanoma2

Targeted therapy1

Approximately5

Prognostic1

Mortality7

Metastasis free2

Significantly improved1

Epithelial1

Women43

Therapeutic1

20211

Centers for Diseas2

Centre1

Early breast cancer4

Biomarkers1

Regimens3

Newly diagnosed1

Hormone6

Risk factors1

Locally1